PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions.
The corrected release reads:
SCIENCE EXCHANGE AND SOLVEBIO ANNOUNCE THAT SOLVEBIO WILL BE LISTED ON THE SCIENCE EXCHANGE MARKETPLACE
Science Exchange and SolveBio are excited to announce that SolveBio will now be available from the Science Exchange marketplace. This will make SolveBio’s cutting-edge translational medicine software solution instantly available to pharmaceutical and biotech companies around the world from the Science Exchange marketplace. SolveBio enables pharmaceutical, biotech, and CDx R&D teams to maintain a real-time, collaborative, in-depth view into targets, biomarkers, and clinical trials and effectively use molecular knowledge. The listing of SolveBio strengthens Science Exchange’s market-leading position as the fastest way to bring innovative scientific services to early stage drug development.
“We are very excited to be developing a strategic relationship with Science Exchange and to work with their outsourced marketplace for scientific research”, said Mark Kaganovich, CEO of SolveBio, “We firmly believe that our relationship with Science Exchange will streamline and expedite the process by which customers deploy SolveBio technology and we look forward to working with our colleagues at Science Exchange”. SolveBio helps life science companies monitor and integrate intelligence generated by internal teams, collaborators, and external feeds in real-time to adopt a truly translational approach to the development of therapeutics and diagnostics.
“Science Exchange is very pleased to offer the services of SolveBio through our marketplace and concierge service”, said Elizabeth Iorns, CEO of Science Exchange. “Rapid access to innovative new technologies is critical to our clients. SolveBio is a great example of a new technology solution that we are excited to make instantly available to our clients”. Science Exchange is the fastest and easiest way for top R&D driven companies to access new innovative service providers. All 3000+ Science Exchange service providers have been pre-qualified and have in place pre-established contracts that enable scientists to instantly orders services from the Science Exchange marketplace. SolveBio’s innovative technology for identifying new insights from large multi-omics and clinical datasets can be accessed immediately by visiting the Science Exchange marketplace.
About Science Exchange:
Science Exchange is the world’s leading marketplace for outsourced research. Science Exchange provides an efficient procure-to-pay platform for ordering services from the world’s largest network of scientific service providers. Through Science Exchange, clients gain access to 3000+ qualified service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. This increases scientists access to innovation and significantly improves their productivity because they are freed up from the administrative tasks and delays associated with sourcing, establishing and managing supplier contracts.
At an organizational level, the Science Exchange enterprise program enables organizations to consolidate the long tail of research outsourcing spend into a single strategic supplier relationship driving significant efficiency and cost savings. To date, Science Exchange has raised over $30 million from Maverick Capital Ventures, Union Square Ventures, Index Ventures, OATV, the YC Continuity Fund, and others. For more information visit www.scienceexchange.com.
SolveBio was founded in 2013 with the mission of building a cutting-edge Translational medicine solution. In partnership with some of the leading pharmaceutical, diagnostics, and CDx organizations in the world, SolveBio has developed technology to enable the use of multi-omics and clinical outcomes data for therapeutic and diagnostic development. SolveBio’s core technology allows it to index, harmonize, and link complex biological data in real-time: external data sources are continuously processed and connected to proprietary internal customer information. This allows biotech, pharma, and diagnostic customers to maintain a real-time, collaborative, in-depth view into targets, biomarkers, and clinical trials and effectively use molecular knowledge. SolveBio is based in New York and has raised $4.5M to date, from Andreessen Horowitz, Max Levchin, Faridan Ventures, Nat Turner, and other leading technology and life sciences investors.